Skip to content

Monte Rosa Therapeutics, Inc. GLUE Other operating expenses

Other operating expenses at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$98.75M+21.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$118.52M+22.8%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$151M+0.7%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$159.55M+40.2%
TG Therapeutics logo
TG TherapeuticsTGTX
$73.14M+89.0%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$60.02M+26.0%

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.76B+361%

Profitability

See full
Operating margin-345.2%
Net margin-302.6%
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%
Debt / equity0.1×-0.1×
Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s other operating expenses?
Monte Rosa Therapeutics, Inc. (GLUE) reported other operating expenses of $54.24M in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s other operating expenses changed year-over-year?
Monte Rosa Therapeutics, Inc.'s other operating expenses increased by 32.6% year-over-year, from $40.89M to $54.24M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s other operating expenses has grown at a 25.0% compound annual growth rate (CAGR), from $72.88M to $177.88M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.